Trxc Stock Buy Or Sell 〈LATEST × REVIEW〉

: Leading up to its acquisition, the company reported a Q2 2024 revenue of $2.2 million but sustained a net loss of $25.7 million for the same period. Investment Outlook

: In March 2021, the company changed its name from TransEnterix to Asensus Surgical to align with its focus on "Performance-Guided Surgery". trxc stock buy or sell

The ticker is no longer active for trading. TransEnterix, the company originally associated with that symbol, rebranded as Asensus Surgical and changed its ticker to ASXC in March 2021. Subsequently, Asensus Surgical was acquired by KARL STORZ and its stock was officially delisted in August 2024. Stock Status and Delisting : Leading up to its acquisition, the company

Since the company is now , it is not possible to buy or sell shares on public markets. : KARL STORZ acquired the company primarily for

: KARL STORZ acquired the company primarily for its Senhance Surgical System and the development of the next-generation LUNA™ System , aiming to integrate these into their global endoscopy portfolio.